Bifogade filer
PDF
Kurs
-1,14%
Kalender
| Tid* | ||
| 2026-02-06 | 08:30 | Bokslutskommuniké 2025 |
| 2025-10-24 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-04-25 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-04-03 | N/A | Årsstämma |
| 2025-02-05 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | Extra Bolagsstämma 2024 |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-10 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2024-04-09 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2023-05-02 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-05 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2022-04-04 | - | Årsstämma |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2021-05-10 | - | Årsstämma |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2020-04-02 | - | Årsstämma |
| 2020-03-10 | - | Extra Bolagsstämma 2020 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | Extra Bolagsstämma 2019 |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-09 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2019-04-08 | - | Årsstämma |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-20 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-10 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2018-04-09 | - | Årsstämma |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2017-05-22 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2017-02-20 | - | Extra Bolagsstämma 2017 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-19 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2016-05-24 | - | Årsstämma |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2015-05-06 | - | Årsstämma |
| 2015-05-06 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2014-06-03 | - | Årsstämma |
| 2014-05-09 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-21 | - | Bokslutskommuniké 2013 |
| 2014-02-12 | - | Extra Bolagsstämma 2014 |
| 2013-11-06 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-22 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-03 | - | Kvartalsrapport 2013-Q1 |
| 2013-05-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2013-05-02 | - | Årsstämma |
| 2013-04-03 | - | Extra Bolagsstämma 2013 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-11-21 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-22 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-04 | - | Årsstämma |
| 2012-05-04 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-21 | - | Bokslutskommuniké 2011 |
| 2011-11-21 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-22 | - | Kvartalsrapport 2011-Q2 |
| 2011-07-20 | - | Split EPIS B 6:1 |
| 2011-06-30 | - | Årsstämma |
| 2011-05-21 | - | Kvartalsrapport 2011-Q1 |
| 2011-05-13 | - | Extra Bolagsstämma 2011 |
| 2011-05-02 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-18 | - | Bokslutskommuniké 2010 |
| 2010-08-30 | - | Extra Bolagsstämma 2010 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Episurf Medical hosted a CMD on 16 November at which it discussed the state of the company and its long-term plans. International expansion will be even more important in the future, in our view. The company is still suffering from the effects of the pandemic, and Q3 sales were thus lower than we expected, though its operating losses were in line with our forecast. We reiterate our fair value for Episurf of SEK3.3-9.3.
CMD summary. Episurf Medical hosted a CMD on 16 November, which focused on its plans and product portfolio and talks by Key Opinion Leaders on the data and results for the Episealer Implant system. We believe the company is in a significantly better position to market its implant system than it was a few years ago given the large amount of clinical data that has emerged and matured in recent years. We see a TAM of cUSD2bn over time in the sub-segments of the orthopaedic market that the company is addressing.
The product assortment and geographic reach is increasing. We believe the broadening of the company's product assortment (with a talus implant, MTP implant and patellofemoral implant in addition to its knee implant system) is a positive, especially given that some of the newer implants do not require PMAs to receive approval in the US. The company is also set to continue to introduce products in new geographical markets from 2023.
Foundation for sales growth appears to be in place. We believe the company's broader product assortment, greater geographical reach, and the emergence and maturation of more clinical data combined with increased usage per client (as they become more familiar and comfortable with the products) will drive sales growth. Thus, all the prerequisites for sales growth are in place, in our view.
Fair value of SEK3.3-9.3 reiterated. The company has continued to develop its data set, and the clinical experience among users is rapidly increasing. In the orthopaedic implant market, data and user experience are important sales drivers, and although sales in absolute terms have not yet taken off sharply, we believe the company is better positioned now to see growth materialise in the coming years.
Click here to view the full report. (GetReports.aspx (dnb.no) (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_204845.pdf&Sid=1-9HRQPCA))
Patrik Ling | DNB Markets | Equity Research | Senior Analyst Healthcare
DNB Bank ASA
Regeringsgatan 59 | Stockholm | Sweden
E-mail: patrik.ling@dnb.se| www.dnb.no